S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: A meta-analysis

Table 1 Characteristics of four included studies

Ref.	Year	Country	Study design	Treatment groups	No. of patients	Regimen	Mediancycles	EPOCcriteria	Duration
Koizumi et al[16]	2008	Japan	Randomizedphase III study	Group A	148	S-1: 40-60 mg/m2, b.i.d days 1-21 plus cisplatin 60 mg/m2iv, on day 8, q.2.w	4	7	March 2001-Nov 2006
				Group B	150	S-1: 40-60 mg/m2, b.i.d days 1-28, q.2.w	3
Komatsu et al[17]	2011	Japan	Randomizedphase II study	Group A	48	S-1: 40-60 mg/m2,b.i.d days 1-14 plus irinotecan 75 mg/m2 iv, on days 1 and 15, q.4.w	3	6	Aug 2003-April 2007
				Group B	47	S-1: 40-60 mg/m2, b.i.d days 1-28, q.2.w	2
Narahara et al[18]	2011	Japan	Randomizedphase III study	Group A	155	S-1: 80 mg/m2, b.i.d days 1-21 plus irinotecan 80 mg/m2iv, on days 1 and 15, q.5.w	4	6	June 2004-April 2007
				Group B	160	S-1: 80 mg/m2, b.i.d days 1-28, q.6.w	3
Wang et al[19]	2013	China	Randomizedphase II study	Group A	41	S-1: 40-60 mg/m2, b.i.d days 1-14 plus paclitaxed 60 mg/m2iv, on days 1,8 and 15, q.4.w	6	7	Jan 2008-Dec 2011
				Group B	41	S-1: 40-60 mg/m2, b.i.d days 1-14, q.4.w	5

Group A: S-1-based combination therapy; Group B: S-1 monotherapy. EPOC: Effective practice and organisation of care.